Source: https://iqwig.de/en/projects-results/projects/health-economic/g14-07-cabozantinib-assessment-according-to-35a-para-1-sentence-10-social-code-book-v-dossier-assessment.6275.html
Timestamp: 2019-12-08 03:17:30
Document Index: 414760015

Matched Legal Cases: ['§35', '§35', '§ 35', '§35', '§35', '§35']

www.iqwig.de - [G14-07] Cabozantinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
[G14-07] Cabozantinib - Assessment acco…
[G14-07] Cabozantinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Commission awarded on 2014-07-22 by the Federal Joint Committee (G-BA)
Dossier assessment [PDF, 137 kB] (German version) Further documents
In accordance with § 35a (para. 1, sentence 10) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Cabozantinib report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
[A18-85] Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
[A17-56] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
[A16-69] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
2014-11-03 Dossier assessment (German version) 137 kB PDF
2015-01-22 A G-BA decision was published.